Drug intelligence / Profile preview

WXD171-MntC

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
Administration: Oral

Overview

WXD171-MntC is a genetically engineered probiotic strain based on *Limosilactobacillus reuteri* (L. reuteri) developed as an oral vaccine candidate against *Staphylococcus aureus* infections. The strain WXD171 serves as a live delivery vehicle, modified with a plasmid-based expression system (pNZ8148-MntC) to display the *S. aureus* manganese transport protein C (MntC) on its cell surface. MntC is a highly conserved antigen involved in metal ion acquisition and is essential for *S. aureus* virulence. By utilizing the probiotic's ability to survive the gastrointestinal tract and interact with gut-associated lymphoid tissues (GALT), WXD171-MntC is designed to induce both mucosal and systemic immunity. This approach aims to provide protection against a range of *S. aureus*-induced conditions, including pneumonia, skin infections, and sepsis. The candidate is currently in the preclinical research stage.

Other names: Limosilactobacillus reuteri WXD171-MntCL. reuteri WXD171-MntC

Targets

MntC (Staphylococcus aureus manganese transport protein C)PLG (Plasminogen)

Beyond the preview

Go deeper on WXD171-MntC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WXD171-MntC.

Explore the full profile